Overview

Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fed Condition

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This is a open Label, balanced, randomized, single dose, two-treatment, two-sequence, two-period, crossover, oral pivotal bioequivalence study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fed condition in healthy, adult human subjects.
Phase:
Phase 1
Details
Lead Sponsor:
IPCA Laboratories Ltd.
Treatments:
Etodolac